2 November 2022 - PHARMAC is seeking feedback on rule 8.1b of the Pharmaceutical Schedule – a unique exception that means any medicine currently used to treat cancer in a paediatric setting is automatically funded without a PHARMAC assessment.

“We are not committing to making any changes,” says PHARMAC’s Chief Executive Sarah Fitt. “At this stage, we need to better understand the difference that rule 8.1b is making to the lives of children with cancer, their family and whānau, and the people who are working hard to treat and support them.”

Read PHARMAC press release